Telomir-1 reactivates tumor suppressor genes in prostate cancer models

Telomir Pharmaceuticals has announced new preclinical data demonstrating that its investigational therapy, Telomir-1, reactivates two critical tumor suppressor genes—MASPIN and RASSF1A—in aggressive prostate cancer models. These genes are often silenced through DNA hypermethylation, a common mechanism in cancer progression. In the studies, Telomir-1 reversed the hypermethylation of MASPIN, restoring its function as a natural defense […] The post Telomir-1 reactivates tumor suppressor genes in prostate cancer models appeared first on Longevity.Technology.